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Study of the intracellular nanoparticle-based
radiosensitization mechanisms in F98 glioma cells
treated with charged particle therapy through
synchrotron-based infrared microspectroscopy
I. Martínez-Rovira, *a O. Seksek, b,c I. Dokic,d,e S. Brons, d A. Abdollahi d,e
and I. Yousef a
The use of nanoparticles (NP) as dose enhancers in radiotherapy (RT) is a growing research ﬁeld. Recently,
the use of NP has been extended to charged particle therapy in order to improve the performance in
radioresistant tumors. However, the biological mechanisms underlying the synergistic eﬀects involved in
NP-RT approaches are not clearly understood. Here, we used the capabilities of synchrotron-based
Fourier Transform Infrared Microspectroscopy (SR-FTIRM) as a bio-analytical tool to elucidate the NP-
induced cellular damage at the molecular level and at a single-cell scale. F98 glioma cells doped with
AuNP and GdNP were irradiated using several types of medical ion beams (proton, helium, carbon and
oxygen). Diﬀerences in cell composition were analyzed in the nucleic acids, protein and lipid spectral
regions using multivariate methods (Principal Component Analysis, PCA). Several NP-induced cellular
modiﬁcations were detected, such as conformational changes in secondary protein structures, intensity
variations in the lipid CHx stretching bands, as well as complex DNA rearrangements following charged
particle therapy irradiations. These spectral features seem to be correlated with the already shown
enhancement both in the DNA damage response and in the reactive oxygen species (ROS) production by
the NP, which causes cell damage in the form of protein, lipid, and/or DNA oxidations. Vibrational features
were NP-dependent due to the NP heterogeneous radiosensitization capability. Our results provided new
insights into the molecular changes in response to NP-based RT treatments using ion beams, and high-
lighted the relevance of SR-FTIRM as a useful and precise technique for assessing cell response to inno-
vative radiotherapy approaches.
1 Introduction
Radiotherapy (RT) is the most important non-surgical modality
for cancer treatment since about 50% of cancer patients
receive RT during the course of their illness. Latest technologi-
cal advances in RT brought a substantial gain in the balance
between the probability of tumor control and the risk of
normal tissue complications. However, despite the use of
state-of-the-art RT approaches, the clinical management of
some radioresistant tumors (such as gliomas) continues being
a challenge since tumor doses are constrained by the sur-
rounding healthy tissue tolerances.
The combination of high-atomic number (Z) nanoparticles
(NP) as radiosensitizers in RT was born in the last decade with
the main goal of enhancing the diﬀerential eﬀect between the
tumor and the surrounding healthy tissue.1 The size of the NP
typically ranges between 1 and 100 nm. Small nanoparticles
have a reduced tendency to accumulate in the body after treat-
ment.2 NP leak preferentially into the tumor through active tar-
geting or passively, through enhanced permeability and reten-
tion (EPR) eﬀects.3
The therapeutic eﬃcacy of RT in the presence of the NP has
been proved in numerous studies using kilovoltage and mega-
voltage photon beams, both in vitro and in vivo (see ref. 4–6,
among others). The initial rationale behind these studies is
the enhanced photoelectric cross section of high-Z NP in com-
parison to water and soft tissue, specially at kilovoltage
energies.7
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However, despite extensive research on NP radiosensitiza-
tion using photon beams, few experimental studies have been
carried out in charged particle therapy. The pioneering study
of Usami and collaborators showed an enhancement in DNA
breaks at the molecular scale (plasmid DNA as a probe) using
platinum-based complexes combined with helium and iron
irradiations.8 The eﬃcacy of the same Pt complexes was later
proved in vitro by the same group.9 An enhancement of radi-
ation eﬀects was also demonstrated in proton therapy10–14 and
carbon therapy15–18 in several biological studies using diﬀerent
types of high-Z NP. An overview of experimental studies on
radiosensitization eﬀects of high-Z compounds in charged par-
ticle therapy can be found in the review of Lacombe and
collaborators.19
The mechanisms involved in the NP-induced amplification
of radiation eﬀects in charged particle therapy is still a matter
of controversy since they seem to diﬀer from the ones in stan-
dard photon RT. Moreover, the radiosensitization eﬀects
involved might be distinct from the well-established pathway
of radiation-induced direct DNA damage.20 The amplified radi-
ation damage in the presence of NP was initially associated to
the increase in the ionizations and electron emissions induced
by the incident ions or the electrons in the secondary tracks
on the NP, resulting in a local dose enhancement.15 Recent
studies showed a significant increase in the yield of low-energy
secondary electrons emitted due to collective electron exci-
tations in the NP (plasmons).21 Other authors proposed that
NP could be activated by projectile induced X-rays emission
(PIXE), being the origin of intra-atomic cascades of electron
emissions.10 At the same time, these electrons enhance cell
damage through the increased production of reactive oxygen
species (ROS). Indeed, several studies have pointed out the
important role of hydroxyl radicals.9,13,14 Furthermore, emer-
ging data supported that radiosensitization eﬀects might be
also driven by biological pathways, such as oxidative stress,
DNA damage induction, cell cycle eﬀects and potential inter-
ference with cell communication.22–25
Both radiation chemistry and biological mechanisms, as
well as distinct cell uptake and cell sensitivity as a function of
NP type (size, shape, coating, etc.), should be considered since
pure physical dose enhancement cannot explain the amplifica-
tion eﬀect observed in biological studies.26 Therefore, there is
an urgent need to understand the mechanisms involved in
these novel approaches to progress on the development of NP-
based therapeutics.
Within this context, the objective of our study is to shed
some light on the NP-based radiosensitization mechanisms at
the molecular level in charged particle therapy through syn-
chrotron-based Fourier Transform Infrared Microspectroscopy
(SR-FTIRM). Infrared microspectroscopy has become a power-
ful tool for examining composition and/or conformational
changes in biomolecules, including proteins, lipids, carbo-
hydrates and nucleic acids.27 FTIRM methods have been exten-
sively used to study cell functionality, cell cycle, cell death and
apoptosis, as well as cell and tissue responses to diﬀerent
treatments (see ref. 27–32, among others). The brilliance of the
infrared synchrotron radiation delivered at the MIRAS beam-
line of ALBA synchrotron allowed an infrared spectroscopic
microanalysis at the single-cell level.
Our previous FTIRM works provided new insights into the
radiosensitization eﬀects of gold NP (AuNP) and gadolinium
NP (GdNP) in photon RT.33–35 In the present study, radiosensi-
tization eﬀects of 1.9 nm AuNP (AuroVist®) and 3 nm GdNP
(AGuIX®) were assessed in F98 glioma cells using several
charged particle beams (proton, helium, carbon and oxygen).
The potential of both NP was demonstrated in previous bio-
logical studies.36–39 However, to the best of our knowledge,
this is the first study that evaluates radiosensitization of NP in
charged particle therapy using SR-FTIRM.
2 Materials and methods
2.1 F98 cell culture
The F98 rat cell line (ATCC® CRL-2397, LGC Standards,
Molsheim, France) used in this study is a glioblastoma cell type
displaying a tumor growth infiltrative pattern within brain tissue.
F98 cells were cultured in high glucose (4.5 g L−1) DMEM
growth medium supplemented with 10% Fetal Calf Serum, 1%
penicillin–streptomycin, 1% glutamine and 1% sodium pyru-
vate at 37 °C with 5% CO2 and 95% humidity. Prior to exper-
imentation, cells were plated in order to be kept in the expo-
nential growing phase at around 75–80% confluence. Two days
prior to irradiation, 500 μL of a 4 × 105 cells per mL suspen-
sion were incubated in each well (48-well microplates) at 37 °C
with 5% CO2 in order to reach a 75–80% confluence rate on
the irradiation day.
2.2 Gd and Au nanoparticles
Before the irradiation protocol, cells were treated with AuNP or
GdNP following our previous protocols.33–35 Gold nano-
particles (1.9 nm AuNP, AuroVist®) were purchased from
Nanoprobes (Yaphank, NY). Prior to treatment, 40 mg of AuNP
were rapidly dissolved in 0.2 mL PBS and filtered through a
0.2 μm centrifugal filter at 15 000g for 8 min. From this stock
solution kept at 4 °C, 500 μg mL−1 were applied on the cells
during 24 hours prior to irradiation. As for gadolinium nano-
particles (3 nm GdNP, AGuIX®), which were purchased from
NH TherAguix (Lyon, France), a 100 mM stock solution was
obtained by solubilization with PBS and kept at 4 °C. From
this solution, 1 mM NP solution was applied on the cells
during 6 hours prior to irradiation. The biochemical eﬀects
induced by the NP prior to the irradiations were previously
assessed by means of SR-FTIRM and are reported in our pre-
vious studies.33–35
2.3 Cell irradiations
Irradiations were carried out at the fixed horizontal beam
experimental station of the Heidelberg Ion Beam Therapy
Center (HIT). Several beams were used for the irradiations:
proton (p), helium (4He), carbon (12C) and oxygen (16O). The
well plates were vertically irradiated and placed at the center of
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a 10 mm-long spread out Bragg peak (SOPB) region centered at
80 mm-depth. The following physical (absorbed) doses were
applied (the energy range, E, and mean dose-averaged LET
values are detailed between brackets):
• p: 4.5, 9, 18.2 Gy (E = 101.9–108.2 MeV u−1; LET = 5 keV);
• 4He: 3.3, 6.7, 13.3 Gy (E = 101.6–107.9 MeV u−1; LET = 22
keV);
• 12C: 2.5, 5, 10 Gy (E = 194.9–206.9 MeV u−1; LET = 96
keV);
• 16O: 1.7, 3.3, 6.7 Gy (E = 228.2–244.2 MeV u−1; LET = 140
keV);
in order to achieve eﬀective biological doses of approximatively
5 GyRBE, 10 GyRBE and 20 GyRBE for each beam
configuration. SOBP beam intensities and energies, (dose-
averaged) LET values, as well as physical doses were computed
using the experimental planning program TRiP.40–42 The range
of doses was selected according to previous radiobiological
studies.42,43
2.4 SR-FTIRM sample preparation
24 hours after the irradiations, cells were specifically prepared
for SR-FTIRM measurements following our previous
protocols.33–35 First, the medium was removed and 100 μL of
0.05% Trypsin-EDTA solution were added to each well and
incubated for 5 minutes. Then, 500 μL of supplemented
DMEM medium were added and the cell suspension was cen-
trifuged at 1500 rpm for 5 minutes. After discarding the super-
natant, the cellular pellet was suspended in PBS and centri-
fuged again at 1500 rpm for 5 minutes. The final pellet was
then re-suspended in 10% formalin neutral buﬀered solution
and incubated for 1 hour at room temperature. Then, samples
were rinsed three times in deionized water. Finally, SR-FTIRM
was performed on dried cells deposited onto CaF2
coverglasses.
2.5 SR-FTIRM data acquisition and data analysis
The Hyperion 3000 microscope coupled to Vertex 70 spectro-
meter (Bruker Optik GmbH, Germany) installed at the infrared
beamline MIRAS of ALBA synchrotron light source was used to
perform the SR-FTIRM measurements. The infrared spectra
were collected using the transmission operation mode of the
FTIR microscope. This microscope is equipped with a 50 μm
liquid nitrogen cooled mercury cadmium telluride (MCT)
detector optimized for operation in a range covering the mid-
infrared spectral region. The FTIRM system is operating with a
36× Schwarzschild magnification objective (NA = 0.65) coupled
to a 36× magnification condenser.
Between 100 to 120 cells were randomly selected to undergo
SR-FTIRM measurements from each sample condition. The
SR-FTIRM spectra were acquired using a single masking aper-
ture size of 7 μm × 7 μm. Single point measurements of indi-
vidual cells were obtained in the mid-infrared range at 4 cm−1
spectral resolution with 128 co-added scans per spectrum. A
background spectrum was collected every 5 measurements in
order to eliminate the residual contamination (water vapor,
CO2) of the room ambient.
Principal Component Analysis (PCA) was performed using
the Orange software (Bioinformatics Lab, University of
Ljubljana, Slovenia)44 in order to evaluate the variations in the
spectral features. Prior to the PCA application, the data was
pre-processed by vector normalized second derivative spectra
(Savitzky–Golay algorithm; 9 smoothing points; 3rd polynomial
order). Vector normalization and PCA were separately per-
formed in the 3025–2800 (‘lipids’) and 1800–950 cm−1 (‘finger-
print’) spectral regions.
A curve-fitting analysis was carried out on the amide I band
to evaluate the relative attribution of each component repre-
senting a type of secondary structure. The second derivative
function was used to assess the minima and, thus, to define
the position and number of Gaussian function energy com-
ponents needed to fit the curve of amide I. The Origin 7.0 soft-
ware (OriginLab Corporation, Northampton, USA) was used to
perform the curve-fitting method. A linear baseline was per-
formed in the amide I range prior to curve-fitting.
In order to evaluate the area under the main spectral bands
(see Table 1), the Rubber-band baseline correction method (32
baseline points) was applied to the raw spectra using
Orange.44 Then, violin plots were generated to assess the prob-
ability density of the data for several spectral ratios that were
used as specific markers for indices of the biochemical
changes. More details can be found in section 3.
3 Results and discussion
SR-FTIRM analysis is presented for several beams (p, 4He, 12C,
16O) and doses in the presence (+NP) and absence (−NP) of nano-
particles. SR-FTIRM details on the biochemical eﬀects induced
by the GdNP and AuNP are reported separately for the fingerprint
(section 3.1.1) and lipids (section 3.1.2) spectral regions.
3.1 SR-FTIRM results on the radiosensitization mechanisms
of GdNP and AuNP in charged particle therapy
PCA on the Savitzky–Golay second derivative data was
employed as an unsupervised method to classify the data and
identify the main sources of variation in the SR-FTIRM spectra
Table 1 Main band assignments in the SR-FTIRM spectra (ν = stretching
vibration; δ = bending vibration; s = symmetric; as = asymmetric)45–49
Main band assignment Specta region
νsPO2
−; deoxyribose/ribose ν C–O (phosphate II; PhII) 1146–1004
νasPO2
− (phosphate I; PhI) 1270–1186
δ N–H; ν C–N (proteins: Amide II, AII) 1590–1483
ν CvO (proteins: Amide I, AI) 1710–1598





ν = C–H (lipids) 3018–3002
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in the presence of nanoparticles (GdNP or AuNP). Fig. 1–4
depict the PCA scores in the fingerprint (1800–950 cm−1) and
in the lipids (3025–2800 cm−1) spectral regions for p, 4He,
12C and 16O irradiations, respectively. The corresponding
loading plots are also shown, which represent the influence of
the variables (wavenumbers) in each principal component.
The first two principal components (PC-1 and PC-2) were used
to explain the diﬀerences among the samples. The averaged
Savitzky–Golay second derivative is also presented in the pro-
teins, DNA and lipids regions in Fig. 5.
3.1.1 Fingerprint region (1800–950 cm−1). Between
1800–1400 cm−1, the absorption is dominated by the peptide
bonds of cell peptides and proteins, including membrane pro-
teins. In particular, the amide I (1700–1600 cm−1) band is due
to the CvO stretching vibration of amide groups of proteins,
weakly coupled with the in-plane NH-bending and the CN-
stretching modes.50 The amide II band, located in the
1600–1480 cm−1 region, is mainly due to the combination of
NH-bending and CN-stretching vibrations.50 Both the amide I
and II bands provide valuable information on the secondary
structure of proteins.50 The region between 1350–950 cm−1
consists in a complex bands pattern due to contributions from
carbohydrates and phosphates associated with nucleic acids
(DNA, RNA). The main bands at 1085 cm−1 and 1238 cm−1 are
assigned to the symmetric and asymmetric stretching
vibrations of phosphodiester bonds in nucleic acids. Finally,
the band in the region 1760–1730 cm−1 is related to the carbo-
nyl ester group stretching in lipids and it will be discussed in
the lipids section (3.1.2).
PCA results performed on the Savitzky–Golay second deriva-
tive (Fig. 1–4, top) show diﬀerences between NP-treated (AuNP
and GdNP) groups and NoNP groups for all ion types, with
some overlapping in some of the configurations. An analysis of
the PCA loading plots reveals that most of the variance
accounting for the separation between groups is associated
with protein modifications in the region 1700–1600 cm−1
(amide I). The percentage of the total variance described by
the first and second principal components is 60–80% and
30–10%, respectively, depending on the configuration.
Fig. 5 (top) shows the vector normalized Savitzky–Golay
second derivative of the averaged absorbance spectra in the
protein spectral region. The conformation changes in the
amide I can be clearly seen in both NP treatments, especially
in the case of proton and helium irradiations. Spectra decon-
volution of the amide I region was performed by means of
curve-fitting to precisely evaluate the diﬀerences among the
secondary structures of proteins for the several NP treatments,
as it can be seen in Fig. 6. The deconvoluted spectra of the
amide I band showed a composite of six bands, which are
reported in Table 2.51,52 Changes in the band around
1628 cm−1 were observed, which is assigned to the vibrational
modes of β-sheet structural components.51,52 The β-sheet
intensity increased upon both NP treatments with respect to
the absence of NP. Previous works correlated an increase in
the β-sheet secondary structure with the hallmark character-
istics of cell death,32,53 as well as to lipid-auto-oxidation pro-
ducts that deform the protein secondary structure.54
Therefore, the modifications encountered in the protein spec-
Fig. 1 Proton beam irradiations. SR-FTIRM results on the radiosensitization mechanisms of GdNP and AuNP in charged particle therapy. The PCA
scores and the loading plots are presented in the ﬁngerprint (1800–950 cm−1, top) and lipids (3025–2800 cm−1, bottom) spectral regions in the
absence (NoNP; blue) and in the presence of AuNP (red) and GdNP (green) for 5 GyRBE (left) and 20 GyRBE (right).
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Fig. 2 Helium beam irradiations. SR-FTIRM results on the radiosensitization mechanisms of GdNP and AuNP in charged particle therapy. The PCA
scores and the loading plots are presented in the ﬁngerprint (1800–950 cm−1, top) and lipids (3025–2800 cm−1, bottom) spectral regions in the
absence (NoNP; blue) and in the presence of AuNP (red) and GdNP (green) for 5 GyRBE (left) and 20 GyRBE (right).
Fig. 3 Carbon beam irradiations. SR-FTIRM results on the radiosensitization mechanisms of GdNP and AuNP in charged particle therapy. The PCA
scores and the loading plots are presented in the ﬁngerprint (1800–950 cm−1, top) and lipids (3025–2800 cm−1, bottom) spectral regions in the
absence (NoNP; blue) and in the presence of AuNP (red) and GdNP (green) for 5 GyRBE (left) and 20 GyRBE (right).
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Fig. 4 Oxygen beam irradiations. SR-FTIRM results on the radiosensitization mechanisms of GdNP and AuNP in charged particle therapy. The PCA
scores and the loading plots are presented in the ﬁngerprint (1800–950 cm−1, top) and lipids (3025–2800 cm−1, bottom) spectral regions in the
absence (NoNP; blue) and in the presence of AuNP (red) and GdNP (green) for 5 GyRBE (left) and 20 GyRBE (right).
Fig. 5 All ions (p, 4He, 12C, 16O; from left to right). SR-FTIRM results on the radiosensitization mechanisms of GdNP and AuNP in charged particle
therapy. Savitzky–Golay second derivative of the averaged absorbance spectra in the absence (NoNP; blue) and in the presence of AuNP (red) and
GdNP (green) in the proteins (1700–1350 cm−1, top), DNA (1350–950 cm−1; middle) and lipids (3025–2800 cm−1, bottom) spectral regions.
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tral region could be correlated to an increase in the ROS pro-
duction in the presence of NP, which might cause cell damage
in the form of protein oxidation (as well as lipids and DNA oxi-
dations), leading to an enhancement in the cell death. We also
observed a reduction in the random coil structure content of
proteins, also previously detected in dying cells.55
The ratio of amide I to amide II was also used to show con-
formational changes of proteins, since it is directly related to
the secondary structure of proteins.56 In the violin plots in
Fig. 7, we can clearly observe an increase in the amide I to amide
II ratio, especially in the case of AuNP-treated cells. Following
previous works,56 these results seem to indicate that cellular
protein modifications in the folding and localization have
occurred following an enhanced cell death response induced by
the presence of the NP. Other works correlated the changes in
the amide I and II absorbances with the DNA repairing processes
as a result of the radiation damage produced.57
In the DNA region, several spectral areas appeared to be
modified upon NP treatment for all ion beams, as it can be
seen in the vector normalized Savitzky–Golay second derivative
of the averaged absorbance spectra (see Fig. 5, middle). The
multiple changes in the absorbance and position (shift) of
various peaks probably indicate a number of diﬀerent modifi-
cations of the DNA conformational changes and/or rearrange-
ments attributed to distortions of the DNA double helix in the
presence of NP.
The modifications and the downward shift in the νasPO2
−
(named phosphate I) band at 1238 cm−1 suggest that the
nucleic acid phosphodiester groups suﬀered conformation
Fig. 6 Curve-ﬁtting analysis of the amide I band in the absence (NoNP; blue) and in the presence of AuNP (red) and GdNP (green) (4He). The base-
line-corrected spectrum was ﬁtted with six Gaussian band proﬁles by approximating the number and their positions using the minima of the second
derivative function, which ﬁtted the experimental curve (in black).
Table 2 Spectra deconvolution of the amide I band. Assignment of the
six Gaussian band proﬁles encountered in the curve-ﬁtting analysis51,52
Band assignment Wavenumber
Side chain 1619 cm−1
β-Sheet 1628 cm−1
Random coil 1638 cm−1
α-Helix 1655 cm−1
β-Turn 1680 cm−1
β anti-parallel sheet 1691 cm−1
Fig. 7 All ions (p, 4He, 12C, 16O; from left to right); 20 GyRBE. SR-FTIRM results on the radiosensitization mechanisms of GdNP and AuNP in
charged particle therapy. Distribution of the relative intensities of the amide I (AI) to amide II (AII) spectral band ratio in the absence (NoNP; blue) and
in the presence of AuNP (red) and GdNP (green). See Table 1 for more information on the bands assignment.
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modifications in the DNA backbone, such as partial transitions
between B-DNA to A-DNA structures due to nucleotide base
damage.46,57,58 We also observe changes in the symmetric
phosphate stretching band of phosphodiester nucleic acids
(1085 cm−1; phosphate II), which was correlated with the
degree of intermolecular interactions in the nucleic acids.28
A series of peaks related to ribose and deoxyribose –C–O
and –PO2 stretching vibrations are located in the
1170–995 cm−1 range. The second derivative plot shows
changes in these infrared bands in NP-treated cells, specially
in the peaks around 1060 and 1020 cm−1, suggesting changes in
the deoxyribose/ribose structures. They were reported to be corre-
lated with non-repaired damage in the DNA structure.53 In par-
ticular, the furanose C–O stretching at 1020 cm−1 is an important
marker for base-pairing and base-stacking in RNA.59 This might
indicate base cleavage reactions, probably due to ROS damage or
DNA repairing processes.60 Previous articles related these
changes with modifications in the structure of the RNA that
could induce the formation of altered proteins as a result of the
incorrect translation processes.59 We observed an increase in
such modifications with the presence of both types of NP.
The band near 965 cm−1 is assigned to the ν C–C/C–O
stretching vibration involved in the deoxyribose and phosphate
moiety of the DNA backbone.47 Modifications in this band
were previously related to single-strand breaks (SSB), double-
strand breaks (DSB), crosslinks and deoxyribose
damage.28,57,60,61 The intensities in the phosphate I and phos-
phate II bands (with respect to the amide II band) correlate
inversely with cell death, as detailed in previous works.46,56 In
the violin plots of Fig. 8, AuNP-induced DNA damage is
expressed by the decrease in the PhI and PhII bands, which
might indicate DNA condensation.28,29,46,53,56,57 A reduction on
the absorbance of the phosphate I band was also reported upon
oxidative stress.48
The combination of all these spectral changes showed NP-
induced DNA damage in diﬀerent groups of the DNA mole-
cule, which seems to correspond to the course of cell death
processes. However, unraveling the specific NP-induced cell
processes is a complex task due to the multiple contributions
in this region of the spectral range.
Finally the distinct LET of the several beams could be the
responsible of the diﬀerences observed in the NP-induced bio-
chemical modifications between ions, which might be due to
distinct radiation-induced lethal eﬀects. Despite an increase in
the ROS production was reported in ion beams, an enhanced
DNA-damage complexity and accumulation of non-repairable
DSB was observed in the case of high LET particles.42 This,
combined with the presence of NP, might induce a diﬀerence
of lethal eﬀect on the cells as a function of the LET.
3.1.2 Lipids region (3025–2800 cm−1). The lipids region is
mainly dominated by the symmetric and asymmetric stretch-
ing modes of methylene and methyl groups, mainly present in
Fig. 8 All ions (p, 4He, 12C, 16O; from left to right); 20 GyRBE. SR-FTIRM results on the radiosensitization mechanisms of GdNP and AuNP in
charged particle therapy. Distribution of the relative intensities of the phosphate I (PhI) and phosphate II (PhII) bands with respect to the amide II (AII)
in the absence (NoNP; blue) and in the presence of AuNP (red) and GdNP (green). See Table 1 for more information on the bands assignment.
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the hydrocarbon acyl chain length of lipids, and to a lesser
extend in proteins. Specifically, the intensities of the bands
around 2852 cm−1 and 2922 cm−1 correspond to the CH2 sym-
metric and asymmetric stretching, respectively, while the
peaks at 2874 cm−1 and 2959 cm−1 are associated to the CH3
symmetric and asymmetric stretching.62 The region around
3010 cm−1 is originated from unsaturated fatty acids. In
addition to the bands in the 3025–2800 cm−1 spectral range,
Fig. 9 All ions (p, 4He, 12C, 16O; from left to right); 20 GyRBE. SR-FTIRM results on the radiosensitization mechanisms of GdNP and AuNP in
charged particle therapy. Distribution of the relative intensities of the CH2/CH3, CH2 stretching ratio, CH/CH2 and CvO ester/lipids spectral band
ratios in the absence (NoNP; blue) and in the presence of AuNP (red) and GdNP (green). See Table 1 for more information on the bands assignment.
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the band from 1760–1730 cm−1 is assigned to the ester CvO
stretching of the phospholipids in the cellular membrane, and
it is not overlapped by contributions from proteins and DNA.45
The PC1–PC2 scores scatter plots in the lipids region
(Fig. 1–4, bottom) display well-separated clusters between NP-
treated groups (GdNP and AuNP) and NoNP groups, mostly
along PC-1, for most of the ion beams and doses. PCA
suggested a more marked diﬀerence for AuNP as the PCA
scores showed a clearer separation from NoNP' groups. In all
cases, the first two principal components explain around 50%
and 10–15% of the total variance, respectively. The corres-
ponding loading plots demonstrated that NP-treated groups,
and specially AuNP-treated cells, are mainly correlated with
conformational changes in the CHx vibration bands. Despite
very subtle shifts can be observed in some lipid bands, the
position of the most intense bands is preserved in all configur-
ations (see Fig. 5).
The most important markers for conformational disorders
in the cell membrane are the changes in the intensity in the
lipids spectral area. In particular, the ratios between the areas
of several absorption bands associated to lipids (CH2/CH3, CH2
stretching ratio, CH/CH2 and carbonyl ester to lipids) are pre-
sented in Fig. 9 and detailed hereafter. They provide relevant
information on the lipids biophysical properties and chemical
state modifications within the cell membrane, such as to lipids
structure, chain length, oxidative stress, degree of unsaturation
and membrane peroxidation.63 These ratios provided indications
on the biochemical eﬀects of the NP treatment on the cells.
• The asymmetric CH2/CH3 ratio is associated with the
hydrocarbon acyl chain length of lipids (increases with chain
length). Petibois et al. correlated a reduction of CH2 /CH3 with
membrane phospholipid free radical attacks during oxidative
stress.48 In our study (see Fig. 9), a slight decrease was
observed in AuNP-treated cells with respect to NoNP for all ion
beams and doses. In the case of GdNP, no significant changes
in the CH2/CH3 ratio were observed.
• The CH2 symmetric to CH2 asymmetric stretching ratio
(CH2 stretching ratio) is another way to assess cell membrane
morphology alterations.29,64 In particular, a decrease in the CH2
stretching ratio was associated to an increase in the membrane
rigidity as a consequence of the presence of membrane stabiliz-
ing agents or lipid raft aggregates, which are formed in dying
cells.64 Fig. 9 depicts the CH2 stretching ratio. In the presence
of AuNP, there is a decrease in the CH2 stretching ratio.
• The ratio between unsaturated fatty acids
(3018–3002 cm−1) to the symmetric CH2 stretching provides a
good index for unsaturation.45 In Fig. 9, we detect a slightly
higher concentration of unsaturated bonds in the lipid chains
after AuNP treatment with respect to NoNP. The level of unsa-
turation of the fatty acids in the membrane has a high impact
on the characteristics of the membrane. In particular, an
increase of unsaturated fatty acids leads to alterations in the
membrane fluidity,29 which can highly aﬀect functional pro-
perties of the cell.65,66
• The distribution of the carbonyl ester group stretching
band (1760–1730 cm−1) found in non-hydrogen bonded and
hydrogen-bonded states in phospholipids was reported to be a
good indicator of lipid peroxidation.49 Fig. 9 shows the distri-
bution of this band with respect to the area under the lipids
region in order to normalize to cell thickness diﬀerences.49 We
detected an increase of the carbonyl ester stretching band in
the presence of both types of NP, particularly in the case of
AuNP-treated cells. The increase was associated to an increase
of oxidized lipids present in the membrane of dying cells or in
cells under oxidative stress due to lipid peroxidation
products.32,49
Our results showed that RT-NP treatments induced several
modifications in the lipids spectral range, which might involve
a wide range of biological processes. The modifications
observed regarding lipids biophysical properties and chemical
state might be related to the oxidative stress produced by the
production of ROS from indirect eﬀects of ionizing radiation
in the presence of NP, which has been reported to be the main
responsible of the amplification of the radiation damage
observed in some charged particle therapy studies combined
with NP.8,19 Indeed, the induction of AuNP-related oxidative
stress was previously reported using the same type of NP via
increased production of endogenous reactive oxygen species
and depletion of intracellular antioxidants.36,67 The lipid diﬀer-
ences in cellular response between AuNP and GdNP might be
attributed to the distinct radiosensitization capability of both
NP, which might lead to distinct cell damage/death pathways.
4 Conclusions
The objective of our SR-FTIRM study was to shed some light
on the (Au and Gd) NP-based radiosensitization mechanisms
in F98 cells treated with charged particle therapy (proton,
helium, carbon and oxygen). Thanks to the very high signal-to-
noise ratio of synchrotron-based FTIRM, modifications in the
infrared spectra were assessed at a single-cell level.
Observation of PCA results evidenced the separation between
the NP-treated cells and the NoNP control cells, with some
overlapping in some configurations. PCA in the fingerprint
(proteins and DNA) and lipids regions enabled to distinguish
the biochemical features induced by the nanoparticles on the
main biomolecules present in F98 glioma cells.
In the proteins spectral region, a deconvolution study on
the amide I revealed an increase in the β-sheet secondary
structure in the presence of NP. This, along with examination
of the amide I to amide II ratio, indicated cellular protein
modifications in the folding and localization induced by the
NP. In the DNA region, we revealed a number of structural and
conformational changes in the presence of NP, as well as evi-
dences of DNA fragmentation represented by the decrease in
the νs PO2
− and νas PO2
− bands. In the lipids spectral region,
several specific markers were used as indices of the changes
(CH2/CH3, CH2 stretching ratio, CH/CH2 and CvO ester to
Lipids), which provided relevant information on the changes
induced by the NP in the lipid structure, chain length, oxi-
dative stress, degree of unsaturation and membrane peroxi-
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dation. The modulation of the band intensities specific to
DNA, proteins and lipids might evidence an enhanced pro-
duction of ROS in the presence of NP, as well as an enhanced
DNA damage response, correlated with cell damage/death.
These results are in line with the amplification of radiation
eﬀects induced by NP in previous radiobiological studies in
charged particle therapy. Finally, vibrational features were NP-
dependent since radiosensitization eﬀects diﬀered between
diﬀerent NP (Au/Gd) types.
To conclude, this is the first work that provides new
insights into the radiosensitization eﬀects of nanoparticles in
charged particle therapy through SR-FTIRM. However, moni-
toring the overall biochemical changes in the cell upon NP-
based RT treatmens is a very complex task since it involves a
wide range of biochemical processes. Therefore, the under-
lying biochemical processes implicated in such novel NP-RT
approaches will need to be more thoroughly experimentally
investigated.
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